AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and ...

In trading on Monday, shares of AbbVie crossed below their 200 day moving average of $178.81, changing hands as low as $172.70 per share. AbbVie Inc shares are currently trading down about 12.4% ...

For years, AbbVie's (ABBV) blockbuster rheumatoid-arthritis ... according to the World Health Organization. People with ...